Chemify, a deep-tech company combining chemistry, robotics, and computation with its proprietary Chemputation AI, has raised more than $50 million in an oversubscribed Series B round. The financing will help the company accelerate its mission to become a global leader in digital chemistry, molecular design, and manufacturing.
Wing Venture Capital and Insight Partners co-led the round. Additional investors include 8VC, along with existing backers Triatomic Capital, Blueyard, Rockspring, and Eos. The capital will allow Chemify to expand its Chemputation platform and scale its Chemifarm facilities, which are designed to transform how molecules are designed and produced for medicines and advanced materials.
Earlier this year, Chemify launched its first Chemifarm—a fully automated chemistry facility built to serve as the most advanced laboratory for molecular design and synthesis. The facility integrates the Chemputation platform, which acts as an extensible programming language for chemistry, alongside robotics and the world's largest curated library of validated reactions.
This infrastructure enables rapid, data-driven creation of molecules that were previously difficult or impossible to access. With the new funding, Chemify plans to replicate this model globally, building a network of digital chemistry hubs. The goal is to provide pharmaceutical, biotech, and materials-science companies with on-demand molecule design and manufacturing capabilities.
Chemify will use the Series B proceeds to open a new facility in Silicon Valley, led by Chief Technical Officer Mike Bell. The expansion is intended to compress the timeline from initial concept to final compound. By offering on-demand molecular design, optimization, and synthesis, the company aims to speed up the discovery of new medicines and next-generation materials.
The move positions Chemify to establish a new global standard for how small molecules are developed and manufactured. The company believes its approach can make a meaningful impact on drug discovery and materials science by reducing both time and cost.
"Chemify aims to become the global digital backbone of chemistry, enabling fast design and discovery," said Lee Cronin, CEO and Founder. "Our vision is that Chemify will be able to design and make any molecule on demand for our customers across all of chemistry from drug discovery to new catalysts and electronic materials. The next step in our evolution is nothing short of a revolution in the digitization and automation of chemical discovery and manufacturing."
Cronin founded the company in 2022 as a spin-out from the University of Glasgow. His vision was to reinvent chemistry on a digital foundation, bringing together automation, AI, and data to accelerate the discovery of new medicines and advanced materials while building a scalable, global platform for molecular innovation.
Ansuman Satpathy, a Partner at Wing Venture Capital, said, "Chemify's technology uses automation and physical AI to enable the digitization of chemistry, transforming chemical synthesis from an art to a programmable science. We are excited to support the team's progress as they empower scientists to create novel molecules with unmatched efficiency and precision. Their work has the potential to drive significant advancements in drug discovery and medicine."
Aiden Aceves, Vice President at Insight Partners, added, "Lee is an iconoclast with the wind at his back. Chemify's use of AI to ensure the makeability of complex molecules is a paradigm shift for how medicinal chemistry is done today, and the company's vision is matched by the strong results seen across their early pharma collaborations."
In conjunction with the financing, both Ansuman Satpathy of Wing Venture Capital and Aiden Aceves of Insight Partners have joined Chemify's Board of Directors. Their addition brings strategic guidance as the company moves into its next phase of growth.
Chemify is headquartered in Glasgow, Scotland. The company turns digital code into physical compounds through Chemputation, its fusion of robotics and AI.
Wing Venture Capital was founded in 2013 and works with founders to enable AI-first transformation in business. The firm invests early, leading Seed and Series A financings with hands-on company-building resources. Wing's portfolio includes companies such as Snowflake, Cohesity, Pinecone, Gong, and Rula.
Insight Partners is a global software investor partnering with high-growth technology, software, and internet companies. As of June 30, 2025, the firm has over $90 billion in regulatory assets under management. Insight Partners has invested in more than 875 companies worldwide, with over 55 portfolio companies achieving an IPO. The firm is headquartered in New York City with a presence in London, Tel Aviv, and the Bay Area.
